A nontumorigenic variant of FGF19 treats cholestatic liver diseases. (Q53233233)

12 May 2018

title

A nontumorigenic variant of FGF19 treats cholestatic liver diseases. (English)

1 reference

12 May 2018

author name string

Jian Luo

1

1 reference

12 May 2018

Brian Ko

2

1 reference

12 May 2018

Michael Elliott

3

1 reference

12 May 2018

Mei Zhou

4

1 reference

12 May 2018

Darrin A Lindhout

5

1 reference

12 May 2018

Van Phung

6

1 reference

12 May 2018

Carmen To

7

1 reference

12 May 2018

R Marc Learned

8

1 reference

12 May 2018

Hui Tian

9

1 reference

12 May 2018

Alex M DePaoli

10

1 reference

12 May 2018

Lei Ling

11

1 reference

12 May 2018

language of work or name

English

0 references

publication date

1 July 2014

1 reference

12 May 2018

Science Translational Medicine

published in

1 reference

12 May 2018

volume

6

1 reference

12 May 2018

issue

247

1 reference

12 May 2018

page(s)

247ra100

1 reference

12 May 2018

Bile acids: trying to understand their chemistry and biology with the hope of helping patients

cites work

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Pathogenesis of cholestatic liver disease and therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Mutations in the MDR3 gene cause progressive familial intrahepatic cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Ursodeoxycholic acid for the treatment of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Fifty years of advances in bile acid synthesis and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Endocrine fibroblast growth factors 15/19 and 21: from feast to famine

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Circulating fibroblast growth factors as metabolic regulators--a critical appraisal

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Liver-specific activities of FGF19 require Klotho beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Co-receptor requirements for fibroblast growth factor-19 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Identification of a therapeutic strategy targeting amplified FGF19 in liver cancer by Oncogenomic screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Separating Tumorigenicity from Bile Acid Regulatory Activity for Endocrine Hormone FGF19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Adenovirus-adeno-associated virus hybrid for large-scale recombinant adeno-associated virus production

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Long-term regulated expression of growth hormone in mice after intramuscular gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Comparison of murine cirrhosis models induced by hepatotoxin administration and common bile duct ligation

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Hypercholesterolemia in primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Bile acid transporters and regulatory nuclear receptors in the liver and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

A gene encoding a P-type ATPase mutated in two forms of hereditary cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Transient positivity of antinuclear and anti-smooth muscle antibodies in hepatitis A virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Monitoring hepatic cholesterol 7alpha-hydroxylase activity by assay of the stable bile acid intermediate 7alpha-hydroxy-4-cholesten-3-one in peripheral blood

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Progressive familial intrahepatic cholestasis, type 1, is associated with decreased farnesoid X receptor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Obeticholic acid and budesonide for the treatment of primary biliary cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Primary biliary cirrhosis and cancer risk: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19).

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Altered enterohepatic circulation of bile acids in Crohn's disease and their clinical significance: a new perspective.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Role of bile metabolites in colon carcinogenesis. Animal models.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1126%2FSCITRANSLMED.3009098

10.1126/SCITRANSLMED.3009098

21 January 2018

Identifiers

DOI

1 reference

12 May 2018

PubMed ID

25080475

1 reference

12 May 2018